BLS — BLS Pharmaceuticals Share Price
Last trade - 00:00- AU$255.28m
- AU$250.42m
- AU$74.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.21 | ||
| Price to Tang. Book | 8.32 | ||
| Price to Free Cashflow | 158.9 | ||
| Price to Sales | 3.44 | ||
| EV to EBITDA | 14.4 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 41.92% | ||
| Return on Equity | 70.8% | ||
| Operating Margin | 21.38% | ||
Financial Summary
| Year End 30th Jun | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.47 | 5.23 | 9.65 | 29.29 | 74.23 | n/a | n/a | 103.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +193.86 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Directors
- Last Annual
- June 30th, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- September 23rd, 1998
- Public Since
- December 14th, 2000
- No. of Employees
- 16
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 229,977,671
- Address
- Suite 506, Level 5, 50 Clarence Street, SYDNEY, 2000
- Web
- https://blspharma.com
- Phone
- +61 290787669
- Auditors
- Pitcher Partners
Latest News for BLS
Upcoming Events for BLS
BLS Pharmaceuticals Ltd Annual Shareholders Meeting
BLS Pharmaceuticals Ltd Annual Shareholders Meeting
Half Year 2027 BLS Pharmaceuticals Ltd Earnings Release
Similar to BLS
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Avecho Biotechnology
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
As of Today at 01:39 UTC, shares in BLS Pharmaceuticals are trading at AU$1.11. This share price information is delayed by 15 minutes.
Shares in BLS Pharmaceuticals last closed at AU$1.11 and the price had moved by +184.62% over the past 365 days. In terms of relative price strength the BLS Pharmaceuticals share price has outperformed the ASX All Ordinaries Index by +198.48% over the past year.
There is no consensus recommendation for this security.
Find out moreBLS Pharmaceuticals does not currently pay a dividend.
BLS Pharmaceuticals does not currently pay a dividend.
BLS Pharmaceuticals does not currently pay a dividend.
To buy shares in BLS Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$1.11, shares in BLS Pharmaceuticals had a market capitalisation of AU$255.28m.
Here are the trading details for BLS Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BLS
Based on an overall assessment of its quality, value and momentum BLS Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BLS Pharmaceuticals. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +65.07%.
As of the last closing price of AU$1.11, shares in BLS Pharmaceuticals were trading +45.3% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BLS Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BLS Pharmaceuticals' management team is headed by:
- Anthony Ho - CHM
- Nam Hoat Chua - CEO
- Guy Robertson - CFO
- Patrick Ford - NED
- Peter Hughes-Hallett - NED